EA201492279A1 - Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек - Google Patents

Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек

Info

Publication number
EA201492279A1
EA201492279A1 EA201492279A EA201492279A EA201492279A1 EA 201492279 A1 EA201492279 A1 EA 201492279A1 EA 201492279 A EA201492279 A EA 201492279A EA 201492279 A EA201492279 A EA 201492279A EA 201492279 A1 EA201492279 A1 EA 201492279A1
Authority
EA
Eurasian Patent Office
Prior art keywords
drug
kidney disease
polycystic kidney
prevention
treatment
Prior art date
Application number
EA201492279A
Other languages
English (en)
Other versions
EA036062B1 (ru
Inventor
Хироюки Фудзики
Мики Аихара
Сидзуо Киносита
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of EA201492279A1 publication Critical patent/EA201492279A1/ru
Publication of EA036062B1 publication Critical patent/EA036062B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предметом настоящего изобретения является предоставление комбинированного лекарственного средства, которое оказывает значительный положительный предупреждающий и/или терапевтический эффект при поликистозной болезни почек. Настоящее изобретение представляет лекарственное средство для предупреждения и/или лечения поликистозной болезни почек, содержащее комбинацию толваптана или его пролекарства и производного соматостатина, и способ лечения поликистозной болезни почек с использованием данного лекарственного средства.
EA201492279A 2012-05-31 2013-05-30 Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек EA036062B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653524P 2012-05-31 2012-05-31
PCT/JP2013/065637 WO2013180310A1 (en) 2012-05-31 2013-05-30 Drug for preventing and/or treating polycystic kidney disease

Publications (2)

Publication Number Publication Date
EA201492279A1 true EA201492279A1 (ru) 2015-05-29
EA036062B1 EA036062B1 (ru) 2020-09-22

Family

ID=48670042

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492279A EA036062B1 (ru) 2012-05-31 2013-05-30 Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек

Country Status (31)

Country Link
US (7) US9636382B2 (ru)
EP (1) EP2854815B1 (ru)
JP (4) JP6116591B2 (ru)
KR (2) KR102127180B1 (ru)
CN (2) CN107625953A (ru)
AR (1) AR091205A1 (ru)
AU (3) AU2013268343B2 (ru)
BR (1) BR112014029573A2 (ru)
CA (1) CA2873365A1 (ru)
CO (1) CO7160102A2 (ru)
CY (1) CY1120490T1 (ru)
DK (1) DK2854815T3 (ru)
EA (1) EA036062B1 (ru)
ES (1) ES2654768T3 (ru)
HK (1) HK1206992A1 (ru)
HR (1) HRP20180040T1 (ru)
HU (1) HUE035158T2 (ru)
IL (2) IL235623A0 (ru)
LT (1) LT2854815T (ru)
MX (1) MX366121B (ru)
MY (1) MY174625A (ru)
NO (1) NO2888775T3 (ru)
NZ (1) NZ630118A (ru)
PH (2) PH12014502558A1 (ru)
PL (1) PL2854815T3 (ru)
PT (1) PT2854815T (ru)
SG (2) SG11201407368VA (ru)
SI (1) SI2854815T1 (ru)
TW (2) TWI704919B (ru)
WO (1) WO2013180310A1 (ru)
ZA (1) ZA201408411B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963659C (en) 2008-09-17 2020-06-23 Chiasma Inc. Use of oral octreotride compositions
TWI704919B (zh) 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
KR20150102083A (ko) 2012-12-28 2015-09-04 오쓰까 세이야꾸 가부시키가이샤 광학 활성 톨밥탄을 포함하는 주사용 데포 제형 및 이의 제조 방법
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
EP3405211A4 (en) * 2016-01-21 2019-10-09 Chiasma Inc. ORAL OCTREOTIDE FOR THE TREATMENT OF DISEASES
WO2019118272A1 (en) * 2017-12-11 2019-06-20 Mayo Foundation For Medical Education And Research Using probenecid to treat polycystic kidney disease
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
EP4015860A4 (en) 2019-08-14 2022-09-28 Autodyn Sys Inc. LOCKING THE CLUTCH SYSTEM WITH THE ACCELERATOR PEDAL AND THE BRAKE PEDAL
JP2022552031A (ja) 2019-10-16 2022-12-15 オートディン シス インコーポレイテッド 新規な構造の回転軸アセンブリー
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US20230158041A1 (en) * 2021-11-22 2023-05-25 Otsuka Pharmaceutical Co.,Ltd. Methods and compositions for treating autosomal dominant polycystic kidney disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450097B1 (en) 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
JP4154765B2 (ja) 1998-09-28 2008-09-24 ダイキン工業株式会社 天井取付型の空気吹出器
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
PT1968990E (pt) 2005-12-27 2015-03-16 Otsuka Pharma Co Ltd Composto de benzoazepina solúvel em água e a sua composição farmacêutica
GB0602639D0 (en) 2006-02-09 2006-03-22 Novartis Ag Organic compounds
WO2007114697A1 (en) 2006-03-31 2007-10-11 Erasmus University Medical Center Rotterdam Novel composition for tumor growth control
MX2008015666A (es) * 2006-06-08 2009-01-12 Novartis Ag Combinacion de analogos de somatostatina con un agonista de dopamina o un antagonista del receptor de hormona de crecimiento.
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
TWI704919B (zh) 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物

Also Published As

Publication number Publication date
JP6724085B2 (ja) 2020-07-15
AU2013268343B2 (en) 2017-06-01
AU2019202158A1 (en) 2019-04-18
CY1120490T1 (el) 2019-07-10
TWI704919B (zh) 2020-09-21
CN104334176A (zh) 2015-02-04
US20170196877A1 (en) 2017-07-13
ZA201408411B (en) 2016-09-28
US11013746B2 (en) 2021-05-25
US11957691B2 (en) 2024-04-16
TWI633887B (zh) 2018-09-01
CA2873365A1 (en) 2013-12-05
US11147821B2 (en) 2021-10-19
IL253441A0 (en) 2017-09-28
PH12014502558B1 (en) 2015-01-21
JP2019001801A (ja) 2019-01-10
HUE035158T2 (hu) 2018-05-02
US20170239265A1 (en) 2017-08-24
BR112014029573A2 (pt) 2017-06-27
NZ630118A (en) 2016-07-29
CN104334176B (zh) 2018-01-02
KR102127180B1 (ko) 2020-06-29
TW201827056A (zh) 2018-08-01
KR20150016597A (ko) 2015-02-12
CN107625953A (zh) 2018-01-26
AU2017202757A1 (en) 2017-05-18
WO2013180310A1 (en) 2013-12-05
PH12018501227A1 (en) 2020-09-14
SG10201609250QA (en) 2016-12-29
MX366121B (es) 2019-06-27
AR091205A1 (es) 2015-01-21
DK2854815T3 (en) 2018-01-22
JP2020117535A (ja) 2020-08-06
HK1206992A1 (en) 2016-01-22
EP2854815A1 (en) 2015-04-08
SG11201407368VA (en) 2015-01-29
ES2654768T3 (es) 2018-02-15
US20190117666A1 (en) 2019-04-25
LT2854815T (lt) 2018-02-12
KR102211354B1 (ko) 2021-02-03
US9669075B2 (en) 2017-06-06
PL2854815T3 (pl) 2018-03-30
US20220241293A1 (en) 2022-08-04
AU2019202158B2 (en) 2020-06-25
PT2854815T (pt) 2017-12-20
JP2017110029A (ja) 2017-06-22
IL235623A0 (en) 2015-01-29
PH12014502558A1 (en) 2015-01-21
MY174625A (en) 2020-05-03
TW201400118A (zh) 2014-01-01
SI2854815T1 (en) 2018-02-28
US9636382B2 (en) 2017-05-02
AU2013268343A1 (en) 2014-11-27
HRP20180040T1 (hr) 2018-02-09
MX2014014476A (es) 2015-02-12
CO7160102A2 (es) 2015-01-15
EA036062B1 (ru) 2020-09-22
NO2888775T3 (ru) 2018-08-04
US20190374549A1 (en) 2019-12-12
US20160058841A1 (en) 2016-03-03
KR20200034811A (ko) 2020-03-31
JP6116591B2 (ja) 2017-04-19
JP6938705B2 (ja) 2021-09-22
JP2015517974A (ja) 2015-06-25
US20150141338A1 (en) 2015-05-21
EP2854815B1 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
EA201492279A1 (ru) Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
EA201691354A1 (ru) Терапевтические ингибирующие соединения
EA201500362A1 (ru) Ингибиторы rho-киназы
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
EA201491500A1 (ru) Способы лечения фиброза
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201491854A1 (ru) Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201491875A1 (ru) Системы и способы лечения индуцированного опиоидами побочного фармакодинамического ответа
EA201792610A1 (ru) Способ лечения неврологического заболевания
EA201200428A1 (ru) Композиция и способ для лечения ожирения
MX2015011567A (es) Halogeno-pirazoles como inhibidores de trombina.
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
EA201692202A1 (ru) Способы лечения сердечно-сосудистых заболеваний
PH12014502065A1 (en) Vesicular formulations
NZ728612A (en) Treatment of androgen deprivation therapy associated symptoms
GB201004761D0 (en) Method

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM